Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...
– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company plans to accelerate the oral formulation of VK2735 following Phase 2 results and has also ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
A small company can now advance its psychedelic into phase 3. Here’s why that matters to other psychedelic biotechs. A small ...
Itepekimab met the primary endpoint in AERIFY-1, reducing COPD exacerbations, but failed in AERIFY-2 despite initial benefits. Lower-than-expected exacerbation rates, possibly due to the COVID-19 ...
Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...
Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 ...
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support ...
Researchers worry that clinical vaccine trials haven't been diverse enough. Ensuring Black and ethnic minority participation in coronavirus vaccine trials is key if we want a truly effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback